THE DEAL, AT A GLANCE
From the announcementImago BioSciences
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedImago BioSciences raised $150M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersImago BioSciences is using $150M in Growth Round financing to advance bomedemstat, an AI-targeted LSD1 inhibitor for blood cancers, into a Phase 3 myelofibrosis trial…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Imago BioSciences · Financing Record
Explore source-linked visual explanations for Imago BioSciences. Unsupported claims are withheld while source review continues.
Record 1646 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →